Evidence map›Paper›PMID 38168268›Full record

ArticlebioRxiv : the preprint server for biology2023

Engineering immunogens that select for specific mutations in HIV broadly neutralizing antibodies.

Rory Henderson, Kara Anasti, Kartik Manne, Victoria Stalls, Carrie Saunders, Yishak Bililign, Ashliegh Williams, Pimthada Bubphamala, Maya Montani, Sangita Kachhap and 16 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 4 institutions in 1 country.

Rory HendersonDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-4301-6382
Kara AnastiDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Kartik ManneDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Victoria StallsDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Carrie SaundersDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Yishak BililignDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Ashliegh WilliamsDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Pimthada BubphamalaDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Maya MontaniDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Sangita KachhapDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Jingjing LiDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Chuancang JaingDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Amanda NewmanDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Derek CainDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Xiaozhi LuDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Sravani VenkatayogiDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Madison BerryDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Kshitij WaghTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Bette KorberTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Kevin O SaundersDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Ming TianProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, 02115.
Fred AltProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, 02115.
Kevin WieheDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Priyamvada AcharyaDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
S Munir AlamDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Barton F HaynesDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Duke Medical Center · USBoston Children's Hospital · USDuke University · USLos Alamos National Laboratory · US

Funding

Nonhuman primate studies for development of a prototype HIV vaccine that induces broadly neutralizing antibodiesUM1AI144371 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2019 to 2025
$190.4M
Virus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Kshitij Wagh · 2017 to 2026
$40.7M
Project 3 - Dynamics of latent HIV-1 reservoirs: High resolution antigenic mapping and strategies to block reboundU54AI170752 · NIAID · DUKE UNIVERSITY · PI Priyamvada Acharya · 2022 to 2026
$32.0M
Targeting early metastable intermediates of the SARS-CoV-2 spike for vaccine and therapeutics developmentR01AI145687 · NIAID · DUKE UNIVERSITY · PI Priyamvada Acharya · 2019 to 2026
$6.9M
Assessing HIV-1 Broadly Neutralizing Antibody Association Pathways for Vaccine Immunogen DesignDP2AI164323 · NIAID · DUKE UNIVERSITY · PI HENDERSON, RORY · 2021 to 2025
$2.4M
Data commons for 'omic, microscopy and analysis core facilitiesS10OD018164 · OD · DUKE UNIVERSITY · PI WRAY, GREGORY A. · 2014 to 2014
$598k
NIAID NIH HHS DP2 AI164323NIAID NIH HHS P01 AI131251NIAID NIH HHS R01 AI145687NIAID NIH HHS U54 AI170752NIAID NIH HHS UM1 AI144371NIH HHS S10 OD018164
6 · The paper itself

Abstract

Vaccine development targeting rapidly evolving pathogens such as HIV-1 requires induction of broadly neutralizing antibodies (bnAbs) with conserved paratopes and mutations, and, in some cases, the same Ig-heavy chains. The current trial-and-error search for immunogen modifications that improve selection for specific bnAb mutations is imprecise. To precisely engineer bnAb boosting immunogens, we used molecular dynamics simulations to examine encounter states that form when antibodies collide with the HIV-1 Envelope (Env). By mapping how bnAbs use encounter states to find their bound states, we identified Env mutations that were predicted to select for specific antibody mutations in two HIV-1 bnAb B cell lineages. The Env mutations encoded antibody affinity gains and selected for desired antibody mutations

Identifiers

PMID38168268
PMCPMC10760096
OpenAlexW4389841789

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.